Three cardiometabolic-related news items have been observed: Better Therapeutics announced the first patient has been enrolled in a pivotal study to evaluate the safety and efficacy of BT-001 for the treatment of T2DM; ProtoKinetix announced it has resumed the Ph1 trials of PKX-001 treated islet cells following a pause due to COVID-19; and Amarin announced it received Great Britain Marketing Authorization approval of Vazkepa (icosapent ethyl) to reduce the risk of CV events in high-risk, statin-treated adults with elevated triglycerides (≥150 mg/dL) and either established CVD or diabetes and at least one additional CV risk factor. Below, FENIX provides highlights and insights for the respective news items.